Helicobacter pylori and peptic ulcer disease.
Medical therapy for duodenal or gastric ulcer disease has traditionally involved gastric acid antisecretory therapy for 4 to 8 weeks to promote initial healing and indefinitely to prevent recurrences of ulcer. The discovery of Helicobacter pylori in most patients with peptic ulcer disease has led to a change in this approach. Therapy designed to eradicate H pylori may facilitate ulcer healing with acid antisecretory agents and, more important, may greatly reduce the incidence of ulcer recurrence, obviating the need for maintenance antisecretory therapy. Regimens designed to eradicate H pylori are difficult to comply with, however, and are associated with adverse effects in some patients. In this article we review the diagnosis and treatment of H pylori infection in patients with peptic ulcer disease and make recommendations regarding the use of conventional ulcer therapies and therapies designed to eradicate H pylori.
Feldman
M
M
Medical Service, Department of Veterans Affairs Medical Center, Dallas, TX 75216.
Peterson
W L
WL
D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D016480:Helicobacter pylori / Q000502:physiology; D006801:Humans; D010437:Peptic Ulcer / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology